Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia
Our study indicates that the administration of nirmatrelvir/ritonavir does not significantly reduce PCC after 3 months and 6 months in a population with high vaccination coverage.
Authors
- Ee Vien Low (ORCID: https://orcid.org/0000-0001-8596-1318)
- Maheshwara Rao Appannan
- Wee Ric Kim (ORCID: https://orcid.org/0000-0003-1912-2940)
- Mohan Dass Pathmanathan (ORCID: https://orcid.org/0000-0001-8385-0315)
- Kalaiarasu M. Peariasamy (ORCID: https://orcid.org/0000-0001-9279-3498)
- Suresh Kumar Chidambaram (ORCID: https://orcid.org/0000-0001-9853-0373)
- Zhi Wei Teh
- Wei Jia Lee (ORCID: https://orcid.org/0009-0008-4062-5829)
- Azah Abdul Samad
- Mastura Ismail
- Y Ten
Institutions
- Ministry of Health (MY)
- Hospital Sungai Buloh (MY)
- Taylor's University (MY)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1186/s12879-024-09679-1
- Citations
- 1
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- Kementerian Kesihatan Malaysia
- National Institutes of Health